Business
Maravai LifeSciences Reports First Quarter 2026 Financial Results
SAN DIEGO, May 07, 2026--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates.
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/58d3006e05fd252525c34b8b8c181dcd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RAfcQap7ydb_7SLWry8ZUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMA--/https://media.zenfs.com/en/business-wire.com/58d3006e05fd252525c34b8b8c181dcd","width":480,"height":210},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hIARwtxSRHWF7PvQUvkqcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI4MA--/https://media.zenfs.com/en/business-wire.com/58d3006e05fd252525c34b8b8c181dcd","width":480,"height":210}},"lazy":false},{"type":"text","content":"First quarter 2026 total revenue up 41% from prior year","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"Base revenue excluding revenue for high-volume CleanCap for commercialized COVID-19 vaccines up 10% from prior year","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, May 07, 2026--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates.","length":313,"tagName":"p"},{"type":"text","content":"Key Financial Results:","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million;","length":91,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Returned to positive free cash flow, generating $4.2 million in the quarter; and","length":80,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Increased full year 2026 Revenue and Adjusted EBITDA guidance.","length":62,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":233,"olType":false},{"type":"text","content":""2026 is off to a strong start, driven by improving demand in our core TriLink base business and continued strength across our higher-margin portfolio," said Bernd Brust, CEO of Maravai LifeSciences. "TriLink base, non-COVID revenue grew 15% year over year, while total TriLink revenue grew 65%. Our disciplined focus on th...